bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. It develops noninvasive diagnostic tests using flow cytometry and automated analysis developed by artificial intelligence (AI). Its diagnostic tests analyze cell populations, including cancer and cancer-related cells, that are indicative of a specific diseased state. Its first product, CyPath Lung, is a noninvasive test that addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening. CyPath Lung is marketed as a Laboratory Developed Test.